Med-IQ
A 2022 Update in Newly Diagnosed and Relapsed Refractory Myeloma: How to Collaboratively Alter the Myeloma Journey With Patients

A 2022 Update in Newly Diagnosed and Relapsed Refractory Myeloma: How to Collaboratively Alter the Myeloma Journey With Patients

Webcast
Continue to Course
Online Course | Specialties: Hematology, Oncology
Released: 2/24/2022
|
Expires: 2/23/2023
|
Max Credits: 1.0
Continue to Course Read Abstract

Faculty
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational
Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Scottsdale, AZ

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, AZ

Activity Planners
Brad Bongiovanni, ND
Director, Medical Affairs
Med-IQ
Baltimore, MD

Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Discuss a personalized approach to quadruplet therapy in patients with newly diagnosed MM
  • Integrate critical management concepts involving treatment duration, switching/combining therapy, and adverse-event profiling to enhance outcomes in RRMM
  • Discuss implementing PROs into shared decision making in the context of treatment administration to optimize adherence and health-related QOL

Target Audience
This activity is intended for hematologist/oncologists, hematology fellows, nurse practitioners, physician assistants, and nurses.

Statement of Need
Patients with multiple myeloma (MM) are living longer, in part because of evolving treatment approaches. These newer treatment modalities, however, have led to increased symptom burden and notable negative effects on health-related quality of life (QOL). To ensure that QOL is maintained, patient-reported outcome measurements (PROMs) should be assessed and evaluated regularly as patients move from diagnosis, treatment, remission, relapse, and end of life.

In addition, clinicians must stay abreast of the ever-changing treatment landscape and how new therapeutic options might affect not only the personalization of induction therapy in newly diagnosed patients but also decision making related to switching, combining, and maintaining therapy when patients develop refractory disease.

Because patient’s treatment preferences are often guided by their perception of QOL, clinicians should strive to explore which factors are most important to the patient and how those factors can be considered with efficacy and safety data in the context of shared decision making.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CME material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: February 24, 2022
Expiration Date: February 23, 2023
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Rafael Fonseca, MD
Consulting fees/advisory boards: AbbVie Inc., Adaptive Biotechnologies, Aduro, Amgen, Bayer Healthcare, Bristol Myers-Squibb, Caris Life Sciences, Celgene Corporation, GlaxoSmithKline, Janssen Pharmaceuticals, Juno Pharmaceuticals, Kite, Merck & Co, Inc., North America, Novartis Pharmaceuticals, OncoTracker, Pharmacyclics, Sanofi-aventis U.S., Inc.

Joseph Mikhael, MD, MEd, FRCPC, FACP
Fees received for promotional/non-CE activities: Amgen, Bristol Myers-Squibb, GlaxoSmithKline, Karyopharm Therapeutics, Janssen Pharmaceuticals North America, Oncopeptides, Sanofi-aventis U.S., Inc.

The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
Nothing in this program is intended to imply that any product use discussed is reimbursed by any government or private payor or that submission of a claim for such use is proper.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CME
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by educational grants from Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme.
 
Copyrighted

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit are available at the "Continue" button below.

  • The current standard of practice for frontline induction therapy in newly diagnosed patients with multiple myeloma remains a triplet regimen, but for how long? 
  • Data showing superiority of quadruplet regimens in the frontline setting continues to push for a possible standard of care update including the recent data release during ASH 2021 from the GMMG-HD7 trial showing that patients who received Isa-RVd achieved an MRD negativity rate of 50.1% at the end of induction therapy vs 35.6% in those who were given RVd alone1
  • Do myeloma patients still need autologous stem cell transplants (ASCTs) given all the progress in other treatments?
  • The MASTER trial also presented results during ASH 2021 examining depths of response in patient receiving Dara-KRd. All risk groups demonstrated improvement in depth of response as measured by MRD testing to depths of 105 to 106 sensitivity2
  • In early relapse trials, anti-CD38 triplet regimen efficacy from the CANDOR, APOLLO, ICARIA, and IKEMA trials reported median PFS of 29, 12, 18 and NR (not reported) months, respectively.3-6
  • Part 2 results of the pivotal STORM study in penta-refractory multiple myeloma showed deep and durable responses with oral selinexor plus low dose dexamethasone7
  • Management of patients with multiple myeloma beyond the clinical-trial setting requires understanding the balance between efficacy, safety and tolerability, and quality of life8

View reference list.

Click “Continue” to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the chapters in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.